Search earnings tickers

ALNY

2025Q4BMO

Alnylam Pharmaceuticals Inc primary · HEALTHCARE · BIOTECHNOLOGY

Report 2026-02-12 · Fiscal end 2025-12-31 · Features as of 2026-02-11

← Earnings history

Street

Consensus EPS1.50

Consensus rev—

EPS high—

EPS low—

Dispersion—

Analysts—

EPS rev net 7d—

EPS rev net 30d—

Consensus Δ 7d—

Consensus Δ 30d—

Options

Implied move3.2%

IV front—

P/C full—

P/C front—

Features as of2026-02-11

Run-up

Close—

Ret 5d-8.4%

Ret 10d-7.8%

Ret 20d-12.9%

Ret 30d-19.2%

Print

Actual EPS

1.25Miss

Estimated EPS1.50

Actual revenue

1.1B

Surprise %-16.7%

Beat / missMiss

Beat streak 40

Beat streak 80

Reaction

1-day stock reaction-1.9%

Implied vs actual

Implied 3.2%Actual 2.4%

Gap reaction-2.4%

Day result-4.3%

Next-day upNo

Realized / IV0.76×

Post tape

Post 5d+9.0%

Post 10d+7.9%

Post volume2.9M

Vol ×10d1.60×

Vol ×20d1.84×

Post range5.6%